Long-Term Insulin Independence and Improvement in Insulin Secretion After Supplemental Islet Infusion Under Exenatide and Etanercept
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Progressive graft dysfunction (GDF) and loss of insulin independence (II) have been invariably observed in islet transplant recipients under the "Edmonton protocol." To reestablish II, we performed supplemental islet infusions (SI) in recipients of allogeneic islet transplant alone, displaying GDF. To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial. METHODS: Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4). Clinical and metabolic profiles were assessed during 18-month follow-up. RESULTS: Long-term II (18 months) was observed in 100% of SI-EXN and in 20% of SI-control (P=0.04). SI-EXN subjects demonstrated restoration of function better than that seen after initial islet infusions. Comparison of SI-EXN and SI-control groups demonstrated better responses in SI-EXN subjects at 3 months post-SI. During the 18 months of follow-up, function was sustained in the SI-EXN subjects better than in SI-controls. Acute effects of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved first and second phase insulin release in response to intravenous glucose tolerance test and suppressed postprandial hyperglucagonemia after mixed meal tolerance test. CONCLUSION: These results suggest that the combination of EXN and etanercept improve engraftment and long-term islet survival and function in subjects undergoing SI. This data, however, must be interpreted with some caution because of small sample size, lack of randomization, and sequential comparison with historical controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“Initial islet transplants were performed as previously described (2,4), the main difference being fresh (ITN) versus cultured islets.”
BackgroundSelf-citationFive-Year Follow-Up After Clinical Islet Transplantation
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., & Shapiro, A. M. J. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2060 · Cited by 1,641
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 1×
“These show improved -cell secretory capacity similar to that observed after EXN administration in patients with type 2 diabetes (26,27).”
Background
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions
Rickels, M. R., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00154 · Cited by 329
Update on Islet Transplantation
McCall, M., & James Shapiro, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007823 · Cited by 226
Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States
Brennan, D. C., Kopetskie, H. A., Sayre, P. H., Alejandro, R., Cagliero, E., Shapiro, A. M. J., Goldstein, J. S., DesMarais, M. R., Booher, S., & Bianchine, P. J. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13458 · Cited by 176
“Three subjects received one additional islet transplant in a different clinical trial upon completion of the originally planned 3-year followup of NIS01 (3).”
Self-citationQi, M., Kinzer, K., Danielson, K. K., Martellotto, J., Barbaro, B., Wang, Y., Bui, J. T., Gaba, R. C., Knuttinen, G., Garcia-Roca, R., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0627-6 · Cited by 96
“that exenatide can improve transplant outcome during follow-up of 6 [28] and 18 months [29].”
The Future of Islet Transplantation Is Now
Bottino, R., Knoll, M. F., Knoll, C. A., Bertera, S., & Trucco, M. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00202 · Cited by 93
“Doctors at the University of Miami and other centers incorporated tumor necrosis factor (TNF) alpha-blockers to supplemental islet infusions (39), where they have been associated with improved results.”
BackgroundAnti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67
Self-citationRecovery of endocrine function after islet and pancreas transplantation
Rickels, M. R. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0294-3 · Cited by 49
“While there may be benefit to the peri-transplant use of glucagon-like peptide-1 (GLP-1) agonists for an anti-apoptotic effect on human islet β-cells [60], clinical studies adding the GLP-1 agonist exenatide have also added etanercept and, so, attribution of benefit cannot be ascribed to exenatide alone [59, 61].”
Metadata
- Authors
- Faradji, R. N., Tharavanij, T., Messinger, S., Froud, T., Pileggi, A., Monroy, K., Mineo, D., Baidal, D. A., Cure, P., Ponte, G., Mendez, A. J., Selvaggi, G., Ricordi, C., & Alejandro, R.
- Venue
- Transplantation
- Published
- 2008-12-27
- Volume
- 86
- Issue
- 12
- Pages
- 1658-1665
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2020680436
- Cited by
- 97
- References
- 7
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.